BIRC6 and acute myeloid leukemia: Carter et al. [10] did not find any prognostic significance for Survivin or XIAP expression in adult AML samples, whereas BIRC6 overexpression is associated with unfavorable clinical features and negatively impacts on the 3-year relapse-free survival in childhood acute myeloid leukemia (AML) [11].